Leading UK-based DMPK provider has taken tenancy at BioHub, Alderley Park, increasing its foothold in the UK.
XenoGesis which was founded in 2011 by Dr Richard Weaver, has seen continued growth at its headquarters at BioCity Nottingham. Now employing 25 members of staff, the business has steadily grown into larger laboratory space, whilst investing in the latest technologies and attracting some of the best DMPK scientists in the region.
XenoGesis prides itself on its consultative approach which, along with collaborative partner relationships, has helped fuel the business’ growth.
BioHub is a member of the BioCity Group and situated on the Manchester Science Parks site in Cheshire. Formerly home to AstraZeneca, the site boasts state-of-the-art laboratories, office space and shared scientific services.
XenoGesis joins the BioHub community from February 2018 as a virtual tenant and will have an increased presence with regular attendance from the newly appointed Global Head of Business Development, Dr Rachel Hemsley, as well as members of the wider team.
Dr Weaver commented, “The North West region is a hotbed of medtech and biotech companies. BioHub is operated by the BioCity Group, so it feels like a natural step for us to have a presence at other BioCity locations. Being part of the BioCity community has provided our business with ideal environment to grow, develop and thrive.”
He continues, “We have established a number of relationships with companies in the North West, some of whom we now work with. This is something I want to see XenoGesis build on. Having a physical presence at BioHub will help us to achieve this, whilst enabling us to become part of the wider BioCity Group community.”
The move to BioHub is part of the business’ wider growth plans for the UK and internationally.
To find out more about XenoGesis, please click here to be taken to the website.